Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy.
Times cited: 39
Genome-Wide association study of event-free survival in diffuse large B-cell lymphoma treated with immunochemotherapy.
Journal of Clinical Oncology.
Times cited: 11
PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.
New England Journal of Medicine.
Times cited: 571